[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 7, Issue 4 (9-2017) ::
Iran J Ped Hematol Oncol 2017, 7(4): 207-215 Back to browse issues page
Evaluating Protective Effects of Silymarin on Liver and Cardiac Side Effects of Chemotherapy Drugs in Childhood Acute Lymphoblastic Leukemia
Mehdi Ghaderian Dr , Nahid Reisi Dr, Alireza Moafi Dr, Safora Farasat Dr
MD Assistant professor of Pediatric Cardiology, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:   (124 Views)
Background: The protective effects of silymarin on liver and heart have been investigated and identified by many researchers. This study evaluates the protective effects of this substance on hepatotoxicity and cardiotoxcity of chemotherapy drugs in leukemic children.
Materials and Methods: In this study, 71 children, aging 2-14 years old, going through the maintenance phase of acute lymphoblastic leukemia (ALL) treatment at Children's Cancer Center of Isfahan University of Medical Sciences (Iran) in 2015 were studied. Two patients died and the remaining patients were divided into intervention and control groups. Intervention group received Mercaptopurin and Methotrexate plus Silymarin 140mg/day and control group were taking only Mercaptopurin and Methotrexate. Liver enzymes, Coagulation tests, Creatine kinase- Muscle and Brain (CK-MB), Ejection fraction and Systolic function (SF) were measured at the first, and 3 and 6 months’ intervals from the commencement of study. The Data was analyzed by using SPSS and P ≤ 0.05 was considered as statistically significant. Associations between variables were analyzed using independent t-test, chi square, and repeated measures ANOVA test.
Results: Mean levels of Alanine aminotransferase in both groups increased significantly at 6 months interval (P=0.01, 0.01, for control and intervention groups respectively). Although increment was more among controls, there were no significant differences between the two groups (P= 0.85). Furthermore, Aspartate aminotransferase and Alkaline phosphatase increased in both groups and the increment was significant in the controls (P=0.001, 0.05, for control and intervention groups respectively). Coagulation tests prolonged in the first 3 months in both groups and the prolongation was more in control group. Changes in CK-MB were not significant in intervention and controls (P=0.07, 0.10, respectively) but ejection fraction and SF decreased in both groups, especially among controls.
Conclusion: It seems that Silymarin can be useful in prevention of hepatotoxicity and cardiotoxcity of chemotherapy drugs for ALL children
Keywords: Acute lymphoblastic leukemia, Cardiotoxity, Hepatotoxicity, Silymarin
Full-Text [PDF 209 kb]   (52 Downloads)    
Type of Study: Research | Subject: Special
Received: 2017/02/5 | Accepted: 2017/04/2 | Published: 2017/09/18
Add your comments about this article
Your username or Email:

Write the security code in the box >



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghaderian M, Reisi N, Moafi A, Farasat S. Evaluating Protective Effects of Silymarin on Liver and Cardiac Side Effects of Chemotherapy Drugs in Childhood Acute Lymphoblastic Leukemia. Iran J Ped Hematol Oncol. 2017; 7 (4) :207-215
URL: http://ijpho.ssu.ac.ir/article-1-341-en.html
Volume 7, Issue 4 (9-2017) Back to browse issues page
Iranian Journal of Pediatric Hematology and Oncology
Persian site map - English site map - Created in 0.208 seconds with 832 queries by yektaweb 3531